| Drug conjugates—an emerging approach to treat breast cancer M Hasan, RK Leak, RE Stratford, DP Zlotos, PA Witt‐Enderby Pharmacology research & perspectives 6 (4), e00417, 2018 | 44 | 2018 |
| Pharmacological, mechanistic, and pharmacokinetic assessment of novel melatonin-tamoxifen drug conjugates as breast cancer drugs M Hasan, MA Marzouk, S Adhikari, TD Wright, BP Miller, MD Matossian, ... Molecular Pharmacology 96 (2), 272-296, 2019 | 39 | 2019 |
| Prevalence of Covid-19 associated symptoms, their onset and duration, and variations among different groups of patients in Bangladesh MT Amin, M Hasan, NMMA Bhuiya Frontiers in public health 9, 738352, 2021 | 30 | 2021 |
| Oxyprenylated phenylpropanoids bind to MT1 melatonin receptors and inhibit breast cancer cell proliferation and migration M Hasan, S Genovese, S Fiorito, F Epifano, PA Witt-Enderby Journal of natural products 80 (12), 3324-3329, 2017 | 24 | 2017 |
| Assessment of the antioxidant, thrombolytic, analgesic, anti-inflammatory, antidepressant and anxiolytic activities of leaf extracts and fractions of Tetracera sarmentosa (L.) Vahl MMN Uddin, MSH Kabir, M Hasan, Z Al Mahmud, NMM Alam Bhuiya, ... Journal of Basic and Clinical Physiology and Pharmacology 29 (1), 81-93, 2018 | 18 | 2018 |
| Novel melatonin, estrogen, and progesterone hormone therapy demonstrates anti-cancer actions in MCF-7 and MDA-MB-231 breast cancer cells M Hasan, E Browne, L Guarinoni, T Darveau, K Hilton, PA Witt-Enderby Breast Cancer: Basic and Clinical Research 14, 1178223420924634, 2020 | 15 | 2020 |
| Co-administering melatonin with an estradiol-progesterone menopausal hormone therapy represses mammary cancer development in a mouse model of HER2-positive breast cancer BR Dodda, CD Bondi, M Hasan, WP Clafshenkel, KM Gallagher, ... Frontiers in oncology 9, 525, 2019 | 15 | 2019 |
| In vivo analgesic, antipyretic and anti-inflammatory potential of leaf extracts and fractions of Eria javanica NMMA Bhuiya, M Hasan, Z Al Mahmud, N Qais, MSH Kabir, F Ahmed, ... Journal of Complementary and Integrative Medicine 14 (1), 2017 | 8 | 2017 |
| Melatonin-tamoxifen hybrid ligands and their effects on breast cancer M Hasan, MA Marzouk, S Adhikari, T Wright, B Miller, B Peckich, ... Cancer Research 78 (13_Supplement), 3915-3915, 2018 | 2 | 2018 |
| Therapeutic efficacy of an alpha-particle emitter labeled anti-GD2 humanized antibody against osteosarcoma—a proof of concept study I Liatsou, Y Fu, Z Li, M Hasan, X Guo, J Yu, J Piccolo, A Cartee, H Wang, ... European Journal of Nuclear Medicine and Molecular Imaging, 1-12, 2023 | | 2023 |
| Assessing the role of X-ray radiation in combination with a DNA-PK inhibitor on cellular activity and adhesion using an in vitro HER2-positive breast cancer model M Hasan, I Liatsou, G Sgouros Cancer Research 82 (12_Supplement), 213-213, 2022 | | 2022 |
| Biopharmaceutical Drug Products: An Overview of Physicochemical Properties and Their Modification M Hasan, R Stratford | | 2021 |
| Abstract P2-01-10: Withdrawn MK Hasan, GF Widhopf II, S Zhang, Z Shen, SP Briggs, TJ Kipps Cancer Research 79 (4_Supplement), P2-01-10-P2-01-10, 2019 | | 2019 |
| Abstract P1-01-05: Wnt5a induces ROR1 to associate with cortactin, which undergoes tyrosine phosphorylation, and enhances migration of breast cancer cells MK Hasan, V Tripple, GF Widhopf, J Yu, S Zhang, BA Parker, TJ Kipps Cancer Research 78 (4_Supplement), P1-01-05-P1-01-05, 2018 | | 2018 |
| Dual inhibition of the PI3k/Akt and MEK5/ERK5 pathways in tamoxifen resistant breast cancer TD Wright, M Hasan, P Witt-Enderby, J Cavanaugh Cancer Research 77 (13_Supplement), 2365-2365, 2017 | | 2017 |
